| Symbol | QGEN |
|---|---|
| Name | QIAGEN N.V. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | HULSTERWEG 82, VENLO, 5912 PL, Netherlands |
| Telephone | +31 773556600 |
| Fax | — |
| — | |
| Website | https://www.qiagen.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001015820 |
| Description | Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The companys sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firms revenue (45% of 2021 sales), followed by EMEA (36%) and Asia-Pacific (19%). Additional info from NASDAQ: |
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
Read moreQIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
Read moreQIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
Read moreQIAGEN übertrifft Prognose für das zweite Quartal 2026 dank solider Umsatzzuwächse seiner Wachstumsträger und bestätigt Jahresprognose
Read moreNew Form SCHEDULE 13G/A - QIAGEN N.V. <b>Filed:</b> 2026-06-05 <b>AccNo:</b> 0000912938-26-000674 <b>Size:</b> 7 KB
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
Read more